Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase i and pharmacological study
Spriggs, D.R.; Robbins, G.; Takvorian, T.; Kufe, D.W.
Cancer Research 45(8): 3932-3936
1985
ISSN/ISBN: 0008-5472 PMID: 4016760 Document Number: 260324
High doses of 1-beta-D-arabinofuranosylcytosine, administered as a continuous i.v. infusion, were evaluated in a Phase I trial in 14 patients with advanced solid tumors. 1-beta-D-Arabinofuranosylcytosine was given at 250 mg/sq m/h for infusions of 12 to 36 h. The mean steady state 1-beta-D-arabinofuranosylcytosine plasma level was 19.6 microM with a range of 9 to 59 microM. The principal toxicity was myelosuppression. An infusion of 18 h was well tolerated by most patients. A Phase II dose of 250 mg/sq m/h for 24 h can be used if platelet support is available. This dose schedule may be useful in the treatment of hematological disorders or in clinical combinations with DNA-damaging agents in the treatment of solid tumors.